Beverage vs. Supplement Ambiguity
The Beverage vs. Supplement Ambiguity describes the regulatory gray area where a liquid product can be legally classified as either a conventional food/beverage or a dietary supplement. As brands increasingly engage in functional premiumization by adding adaptogens, nootropics, and vitamins to drinks, they blur the line between hydration/refreshment and physiological intervention.
Classification depends heavily on the product’s formulation, packaging, product name, volume, marketing claims, and regional jurisdiction. This distinction drastically alters the compliance requirements, permissible ingredients, and marketing capabilities for the product.
The Regulatory Distinction
This distinction is critical for compliance across global markets:
- Conventional Beverages: Typically face stricter safety standards for ingredients. In the US, they must use ingredients that are gras-generally-recognized-as-safe; in the EU and Asia, they often require novel-food-regulations approval. They are heavily restricted to claims based purely on nutritive value but can be marketed broadly as refreshing drinks.
- Dietary Supplements: In the US, these fall under the Dietary Supplement Health and Education Act (DSHEA). They often have more leeway regarding the inclusion of novel botanical extracts and allow for non-nutritive botanical claims (permissible structure-function-vs-drug-claims). While they do not require pre-market fda approval for their ingredients in the same strict manner as conventional foods, they are subject to strict labeling requirements and limitations on medical claims.
The US Market: The Reclassification Trap
Many functional beverage brands attempt to position their products as dietary supplements to make lucrative wellness claims about adaptogens or nootropics. However, the FDA aggressively polices this boundary. If the agency determines that the product is packaged, marketed, or consumed like a conventional beverage—such as being sold in a standard 12oz aluminum can, placed in the beverage aisle, or marketed with terms like “refreshing”—it will regulate the product as a conventional food.
This sudden reclassification often catches brands off-guard. If the product contains non-GRAS ingredients, it is deemed adulterated, triggering warning letters and forcing brands to carefully navigate structure-function claims to avoid illegal medical marketing.
High-Risk Ingredients and Market Restrictions
As the market shifts toward adult-soft-drinks infused with prebiotics, adaptogens, and nootropics, brands frequently operate in complex legal environments. Plant-based compounds like kava, kanna, and cannabinoids fall into severe regulatory gray areas. Beyond FDA scrutiny, products containing these ingredients may face operational hurdles, such as being restricted by certain retail marketplaces or payment processors.
International Approaches: The Chinese Dual Pathway Solution
In China, this ambiguity is managed through a fundamentally different framework based on a positive-list-system. The continuum between food and medicine is legally defined by the national-health-commission-nhc (NHC) through dual-use-substances—botanicals classified as both conventional food and Traditional Chinese Medicine (TCM).
This creates a formal dual regulatory pathway for functional-beverage-regulations:
- General Food Pathway: Brands can seek approval for a raw functional ingredient to be used in conventional foods through the NHC’s three-new-foods-system.
- Health Food Pathway: If an adaptogen is not approved for general food use, brands cannot simply sell it as a conventional beverage. They must pivot to the specialized “Health Food” sector managed by the state-administration-for-market-regulation-samr (SAMR).
The SAMR pathway requires entering either a stringent Registration track (demanding clinical trials for specific health claims) or a Filing track (for pre-approved, low-risk ingredients). When SAMR approves a health food registration, the functional ingredient is deemed acceptable for use exclusively within that specific finished product. This provides a strategic alternative for manufacturers navigating the ambiguity, allowing them to bring functional beverages to market without waiting for the raw ingredient to be approved for widespread conventional food use.
Impact on Unit Economics and Valuation
The hidden compliance costs associated with this ambiguity significantly burden functional beverage brands. To support label claims and safely navigate the strict boundary of structure-function-vs-drug-claims, brands must invest in extensive independent clinical testing and legal review. This is necessary to bridge the clinical-substantiation-gap and prove the efficacy of their ingredients.
Despite the heavy burden on unit economics, there is a substantial upside: brands that successfully navigate this ambiguity, secure defensible IP, and establish validated, compliant claims command significantly higher valuations from strategic acquirers during M&A events.